Overview

A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma

Status:
Not yet recruiting
Trial end date:
2026-10-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of talquetamab versus belantamab mafodotin in terms of overall response rate (ORR) or progression-free survival (PFS).
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC